Sandbox Reserved 1722
From Proteopedia
(Difference between revisions)
| Line 33: | Line 33: | ||
===== ''DRY Motif'' ===== | ===== ''DRY Motif'' ===== | ||
| - | The DRY motif is a proton microswitch that is located near the G-protein binding site C-terminal on TM3 <ref name="Schonegge"/>. It acts as an ion lock when the GPCR is not being activated, preventing unnecessary activation of the G-proteins <ref name="Zhou"/>. This motif is conserved in typical Class A GPCRS however, in MRGPRX2 it is only partially conserved. The arginine is conserved, while the aspartate is replaced by a glutamate and the tyrosine is replaced by a cysteine <ref name="Yang"/> <ref name="Sandoval">Sandoval, A., et al. "The Molecular Switching Mechanism at the Conserved D(E)RY Motif in Class-A GPCRs." Biophysical journal, 111(1), 79-89. https://doi.org/10.1016/j.bpj.2016.06.004 </ref>. | + | The DRY motif is a proton microswitch that is located near the G-protein binding site C-terminal on TM3 <ref name="Schonegge"/>. It acts as an ion lock when the GPCR is not being activated, preventing unnecessary activation of the G-proteins <ref name="Zhou"/>. This motif is conserved in typical Class A GPCRS however, in MRGPRX2 it is only partially conserved. The arginine is conserved, while the aspartate is replaced by a glutamate and the tyrosine is replaced by a cysteine <ref name="Yang"/> <ref name="Sandoval">Sandoval, A., et al. "The Molecular Switching Mechanism at the Conserved D(E)RY Motif in Class-A GPCRs." Biophysical journal, 111(1), 79-89. https://doi.org/10.1016/j.bpj.2016.06.004 </ref>. The replacement of tyrosine for cysteine results in the helices coming closer together, creating a shallower binding pocket.<ref name="Zhou"/> |
===== ''Sodium Binding'' ===== | ===== ''Sodium Binding'' ===== | ||
| Line 60: | Line 60: | ||
[[Image: Drugs.PNG|400px|right|thumb|'''Figure 4''': Structures of Dextromethorphan, Morphine, and Codeine.<ref name="Cao"/>]] | [[Image: Drugs.PNG|400px|right|thumb|'''Figure 4''': Structures of Dextromethorphan, Morphine, and Codeine.<ref name="Cao"/>]] | ||
| - | Many drugs activate MRGPRX2 as a side effect that causes the sensation of itchiness <ref name="Cao"/>. Among these drugs are morphine, codeine, and dextromethorphan.These drugs contain similar chemical features that are also found in (R)- ZINC-3573, introducing the idea of a similar binding mechanism <ref name="Babina"> Babina, M., et al. "MRGPRX2 Is the Codeine Receptor of Human Skin Mast Cells: Desensitization through β-Arrestin and Lack of Correlation with the FcεRI Pathway." Journal of Investigative Dermatology, 141(6), 1286-1296. https://doi.org/10.1016/j.jid.2020.09.017</ref>. | + | Many drugs activate MRGPRX2 as a side effect that causes the sensation of itchiness <ref name="Cao"/>. Among these drugs are morphine, codeine, and dextromethorphan. These drugs contain similar chemical features that are also found in (R)- ZINC-3573, introducing the idea of a similar binding mechanism <ref name="Babina"> Babina, M., et al. "MRGPRX2 Is the Codeine Receptor of Human Skin Mast Cells: Desensitization through β-Arrestin and Lack of Correlation with the FcεRI Pathway." Journal of Investigative Dermatology, 141(6), 1286-1296. https://doi.org/10.1016/j.jid.2020.09.017</ref>. |
Due to mutations in key structural features of typical Class A GPCRS, MRGPRX2, it is able to bind to a variety of substrates that then mediate the signaling pathway for the sensation of itching. | Due to mutations in key structural features of typical Class A GPCRS, MRGPRX2, it is able to bind to a variety of substrates that then mediate the signaling pathway for the sensation of itching. | ||
Revision as of 18:49, 13 April 2022
| This Sandbox is Reserved from February 28 through September 1, 2022 for use in the course CH462 Biochemistry II taught by R. Jeremy Johnson at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1700 through Sandbox Reserved 1729. |
To get started:
More help: Help:Editing |
Human Itch GPCR
| |||||||||||
References
- ↑ Thal, David M., et al. "Structural insights into G-protein-coupled receptor allostery." Nature, Nature Publishing Group, 04 July 2018, https://www.nature.com/articles/s41586-018-0259-z
- ↑ 2.0 2.1 Zhang D, Zhao Q, Wu B. Structural Studies of G Protein-Coupled Receptors. Mol Cells. 2015 Oct;38(10):836-42. doi: 10.14348/molcells.2015.0263. Epub 2015, Oct 15. PMID:26467290 doi:http://dx.doi.org/10.14348/molcells.2015.0263
- ↑ 3.0 3.1 3.2 Zhou Q, Yang D, Wu M, Guo Y, Guo W, Zhong L, Cai X, Dai A, Jang W, Shakhnovich EI, Liu ZJ, Stevens RC, Lambert NA, Babu MM, Wang MW, Zhao S. Common activation mechanism of class A GPCRs. Elife. 2019 Dec 19;8. pii: 50279. doi: 10.7554/eLife.50279. PMID:31855179 doi:http://dx.doi.org/10.7554/eLife.50279
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 Cao, Can, et al. "Structure, function and pharmacology of human itch GPCRs." Nature, Nature Publishing Group, 17 November 2021, https://www.nature.com/articles/s41586-021-04126-6
- ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 Yang, Fan, et al. "Structure, function and pharmacology of human itch receptor complexes." Nature, Nature Publishing Group, 17 November 2021, https://www.nature.com/articles/s41586-021-04077-y
- ↑ 6.0 6.1 Schonegge, Anne-Marie, et al. "Evolutionary action and structural basis of the allosteric switch controlling β2AR functional selectivity." Nature, Nature Publishing Group, 18 December 2017, https://www.nature.com/articles/s41467-017-02257-x
- ↑ Sandoval, A., et al. "The Molecular Switching Mechanism at the Conserved D(E)RY Motif in Class-A GPCRs." Biophysical journal, 111(1), 79-89. https://doi.org/10.1016/j.bpj.2016.06.004
- ↑ Katritch V, Fenalti G, Abola EE, Roth BL, Cherezov V, Stevens RC. Allosteric sodium in class A GPCR signaling. Trends Biochem Sci. 2014 May;39(5):233-44. doi: 10.1016/j.tibs.2014.03.002. Epub , 2014 Apr 21. PMID:24767681 doi:http://dx.doi.org/10.1016/j.tibs.2014.03.002
- ↑ Babina, M., et al. "MRGPRX2 Is the Codeine Receptor of Human Skin Mast Cells: Desensitization through β-Arrestin and Lack of Correlation with the FcεRI Pathway." Journal of Investigative Dermatology, 141(6), 1286-1296. https://doi.org/10.1016/j.jid.2020.09.017
